•
Strong underlying growth driven by business momentum and strict OPEX
discipline; Underlying Revenue +4.2%, Underlying Core Earnings +31.8%,
Underlying Core EPS +32.7%
• Reported results impacted by large one-time gains in FY2017 and Shire related costs in FY2018
• Raising full year outlook on Velcade upside, Growth Driver momentum and OPEX discipline
(BUSINESS WIRE) -- Takeda Pharmaceutical Company Limited (TOKYO:4502):
Underlying Revenue +4.2%, led by Growth Drivers, with growth in every region
Underlying Revenue was solid at +4.2%, with continued strong momentum
from Takeda's Growth Drivers (Gastroenterology, Oncology, Neuroscience
and Emerging Markets), which grew +9.8%.
Key growth products Entyvio (+33.1%) and Ninlaro (+38.0%) were
important contributors to revenue, as were the products acquired from
Ariad in 2017. Every region achieved positive growth versus prior year
(U.S. +9.2%, Japan +4.1%, Europe & Canada +4.3%, Emerging Markets
+2.4%).
Reported revenue decreased -0.1%. Although our Growth Drivers
remained strong, there was a negative impact from foreign exchange rates
(-1.0pp) and divestitures (-3.2pp). The divestiture impact included the
sale of additional products to the Teva JV in FY2017, and Multilab and
Techpool in FY2018.
Underlying Core Earnings +31.8% with margin +5.1pp driven by strict OPEX discipline
Underlying Core Earnings grew +31.8%, reflecting revenue growth and a
margin step-up of 5.1pp, of which two-thirds (3.3pp) was driven by OPEX
improvements. This was a result of the Global OPEX Initiative being
fully integrated into ways of working at Takeda.
Reported operating profit declined -26.6%. This was impacted by two
large one-time gains booked in FY2017: the sale of Wako shares for 106.3
billion yen, and the sale of additional products to the Teva JV.
Furthermore, Takeda booked one-time expenses in FY2018 related to the
proposed acquisition of Shire. Excluding these major one-time items,
Operating Profit grew +64.5%.
Underlying Core EPS was up +32.7%, and reported EPS declined -26.9%
to 162 yen per share, impacted by divestitures and Shire related costs.
Several important pipeline milestones achieved in first half of FY2018
Ninlaro post-stem cell transplant multiple myeloma maintenance
(TOURMALINE-MM3 study), Alunbrig first line ALK+ non small cell lung
cancer (ALTA-1L study), Adcetris frontline CD30+ peripheral T-cell
lymphoma (ECHELON-2 study), and Entyvio subcutaneous formulation in
ulcerative colitis (VISIBLE 1 study) all met their primary endpoints.
7 New Molecular Entities have entered the Phase 1 pipeline since April 2018.
On track with plan to divest non-core assets
Year-to-date Operating Free Cash Flow decreased -29.7% mainly due to
the impact of the sale of additional products to the Teva JV in FY2017.
Sale of real estate and marketable securities generated an additional
44.2 billion yen of cash, and sale of non-core businesses Techpool and
Multilab generated a further 27.2 billion yen.
Net debt / EBITDA ratio is 1.7x, improved from 1.8x in FY2017 Q4 and 2.7x in FY2016 Q4.
Christophe Weber, Chief Executive Officer, commented:
"Strategic
focus and superior execution has driven a robust performance in the
first half of fiscal 2018, as we continue to deliver against our key
priorities to grow the portfolio, strengthen the pipeline, and boost
profitability. Our Growth Drivers continue to contribute significantly
to both revenue and profit, and I am pleased to report that two thirds
of the 510 basis points of underlying Core Earnings margin improvement
was driven by cost discipline as a result of the Global OPEX Initiative.
In
the first half of the year we have also achieved several important
regulatory and financial milestones towards the proposed acquisition of
Shire plc. I want to emphasize that Takeda’s current strategy is
working, and that the Takeda Board, Takeda Executive Team and I are
confident that the acquisition of Shire will enable Takeda to
significantly accelerate its transformational journey to become a
global, values-based, R&D-driven, biopharmaceutical leader
headquartered in Japan."
Reported Results for H1 (April - September) FY2018
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Core
Earnings represents net profit adjusted to exclude income tax expenses,
our share of profit or loss of investments accounted for using the
equity method, finance expenses and income, other operating expenses and
income, amortization and impairment losses on intangible assets
associated with products and other items that management believes are
unrelated to our core operations, such as purchase accounting effects
and transaction related costs.
Underlying
Growth compares two periods (quarters or years) of financial results
under a common basis and is used by management to assess the business.
These financial results are calculated on a constant currency basis and
excluding the impacts of divestitures and other amounts that are
unusual, non-recurring items or unrelated to our ongoing operations.
Attributable to the owners of the company.
Takeda raises its full-year outlook based on Velcade upside, Growth Driver momentum and OPEX discipline
Upward revisions to both Underlying Guidance and Reported Forecast.
FY2018 Underlying Guidance: Raising underlying profit guidance
|
|
|
|
Previous Guidance (growth %)
(May 14, 2018)
|
|
Revised Guidance (growth %)
(October 31, 2018)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Annual Dividend per Share
|
|
|
|
|
- Guidance
assumes one additional therapeutically non-equivalent competitor to
Velcade with intravenous and subcutaneous administration launching in
the U.S. in March 2019, an upside of 35.5 billion yen from the previous
guidance (Global revenue in FY2017: 129.6 billion yen, FY2018: 111.0
billion yen)*
- Underlying Core Earnings margin expansion projected at the higher end of +100-200bps range.
- This
underlying guidance excludes the full fiscal year 2018 estimated
financial impact related to the proposed acquisition of Shire plc by
Takeda.
*(applying constant currency based on FY2018 plan rate)
FY2018 Reported Forecast: Increasing Reported Revenue and Earnings forecasts
|
|
|
|
Previous Forecast
(May 14, 2018)
|
|
Revised Forecast
(October 31, 2018)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exchange Rate
(annual average)
|
|
1 US$=108 yen
1 euro=133 yen
|
|
1 US$=110 yen
1 euro=130 yen
|
|
|
|
|
- The
revised forecast in the table above includes the costs incurred in the
first half of fiscal 2018 related to the proposed acquisition of Shire
plc by Takeda (Profit before tax impact: 19.8 billion yen, Net profit
for the year impact: 16.5 billion yen); however, it does not include any
Shire-related costs anticipated to be incurred in the second half of
the fiscal year. Furthermore, the forecast does not include any
projected earnings from Shire should the closing of the acquisition
occur within fiscal 2018.
- Takeda
estimates the portion of the Shire-related costs to be incurred in
fiscal 2018 to be between 40.0 billion yen and 60.0 billion yen. This
does not include integration costs, debt interest and other financial
expenses as the magnitude of the FY2018 impact from these items will be
dependent on the timing of deal closing.
- A revised financial forecast that excludes the
costs incurred in the first half of fiscal 2018 related to the proposed
acquisition of Shire plc by Takeda is shown below. The previous
forecast of May 14, 2018 also does not include any Shire-related
expenses.
|
|
|
Previous Forecast
(May 14, 2018)
|
|
Revised Forecast
(October 31, 2018)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- A
full year forecast that does include the estimated financial impact of
the proposed acquisition of Shire will be announced by Takeda once a
reasonable assumption has been confirmed.
About Takeda Pharmaceutical Company Limited
Takeda
Pharmaceutical Company Limited is a global, research and
development-driven pharmaceutical company committed to bringing better
health and a brighter future to patients by translating science into
life-changing medicines. Takeda focuses its R&D efforts on oncology,
gastroenterology and neuroscience therapeutic areas plus vaccines.
Takeda conducts R&D both internally and with partners to stay at the
leading edge of innovation. Innovative products, especially in oncology
and gastroenterology, as well as Takeda’s presence in emerging markets,
are currently fueling the growth of Takeda. Approximately 30,000 Takeda
employees are committed to improving quality of life for patients,
working with Takeda’s partners in health care in more than 70 countries.
For more information, visit https://www.takeda.com/newsroom/.
This
release (including any oral briefing and any question-and-answer in
connection with it) is not intended to, and does not constitute,
represent or form part of any offer, invitation or solicitation of any
offer to purchase, otherwise acquire, subscribe for, exchange, sell or
otherwise dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares are being offered to the public
by means of this release. This release is being given (together with any
further information which may be provided to the recipient) on the
condition that it is for use by the recipient for information purposes
only (and not for the evaluation of any investment, acquisition,
disposal or any other transaction). Any failure to comply with these
restrictions may constitute a violation of applicable securities laws.
Unless
specified otherwise, no statement in this release (including any
statement of estimated synergies) is intended as a profit forecast or
estimate for any period and no statement in this release should be
interpreted to mean that earnings or earnings per share for Takeda for
the current or future financial years would necessarily match or exceed
the historical published earnings per share for Takeda.
The
companies in which Takeda directly and indirectly owns investments are
separate entities. In this release, “Takeda” is sometimes used for
convenience where references are made to Takeda and its subsidiaries in
general. Likewise, the words “we”, “us” and “our” are also used to refer
to subsidiaries in general or to those who work for them. These
expressions are also used where no useful purpose is served by
identifying the particular company or companies.
Forward-Looking Statements
This
release and any materials distributed in connection with this release
may contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of operations,
including estimates, forecasts, targets and plans for Takeda. In
particular, this release contains forecasts and management estimates
related to the financial and operational performance of Takeda,
including statements regarding forecasts for FY2018 revenue, Core
Earnings, Operating profit, Profit before income taxes, Net profit
attributable to owners of the company, Basic earnings per share, R&D
expenses, Amortisation and impairment and other income/expense,
Underlying Revenue, Underlying Core Earnings and Underlying Core EPS.
Without limitation, forward looking statements often include the words
such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”,
“aims”, “intends”, “will”, “may”, “should”, “would”, “could”
“anticipates”, “estimates”, “projects” or words or terms of similar
substance or the negative thereof. Any forward-looking statements in
this document are based on the current assumptions and beliefs of Takeda
in light of the information currently available to it. Such
forward-looking statements do not represent any guarantee by Takeda or
its management of future performance and involve known and unknown
risks, uncertainties and other factors, including but not limited to:
the economic circumstances surrounding Takeda’s business, including
general economic conditions in Japan, the United States and worldwide;
competitive pressures and developments; applicable laws and regulations;
the success of or failure of product development programs; decisions of
regulatory authorities and the timing thereof; changes in exchange
rates; claims or concerns regarding the safety or efficacy of marketed
products or products candidates; and post-merger integration with
acquired companies, any of which may cause Takeda’s actual results,
performance, achievements or financial position to be materially
different from any future results, performance, achievements or
financial position expressed or implied by such forward-looking
statements. Neither Takeda nor its management gives any assurances that
the expectations expressed in these forward-looking statements will turn
out to be correct, and actual results, performance or achievements
could materially differ from expectations. Persons receiving this
release should not place undue reliance on forward looking statements.
Takeda undertakes no obligation to update any of the forward-looking
statements contained in this release or any other forward-looking
statements it may make. Past performance is not an indicator of future
results and the results of Takeda in this release may not be indicative
of, and are not an estimate, forecast or projection of Takeda’s future
results.
This
release contains information about products that may not be available
in all countries, or may be available under different trademarks, for
different indications, in different dosages, or in different strengths.
Nothing contained herein should be considered a solicitation, promotion
or advertisement for any prescription drugs including the ones under
development.
Profit Forecast for Takeda for the year ending March 31, 2019
Takeda
is currently in an offer period (as defined in the City Code on
Takeovers and Mergers (the “Code”)) with respect to Shire plc. Pursuant
to Rule 28 of the Code, statements made regarding Takeda’s guidance for
FY2018 (including statements regarding forecasts for FY2018 revenue,
Core Earnings, Operating profit, Profit before income taxes, Net profit
attributable to owners of the company, Basic earnings per share, R&D
expenses, Amortisation and impairment and other income/expense,
Underlying Revenue, Underlying Core Earnings and Underlying Core EPS)
constitute a profit forecast for the year ending March 31, 2019 (the
“Takeda Profit Forecast”).
For
additional information regarding the Takeda Profit Forecast and the
required statement by its Directors that such profit forecast is valid
and has been properly compiled on the basis of the assumptions stated
and that the basis of accounting used is consistent with Takeda’s
accounting policies, please see page 9 of Takeda's Summary of Financial
Statements (Tanshin) for the Six Months Period Ended September 30, 2018.
Takeda Pharmaceutical Company Limited
Takashi Okubo, +81-(0)3-3278-2306
takeda.ir.contact@takeda.com
Takeda Pharmaceutical Company Limited
Kazumi Kobayashi, +81 (0)3-3278-2095
kazumi.kobayashi@takeda.com
